Derivative of isoindigo, indigo and indirubin for the treatment of cancer

• US 6,566,341 B1
• Filed: 12/13/2001
• Issued: 05/20/2003
• Est. Priority Date: 12/13/2001
• Status: Expired due to Term

• Current Assignee: Natrogen Therapeutics International, Inc.
• Original Assignee: Natrogen Therapeutics, Inc.
• Inventors: Liu, Xiaomei, Wang, Longgui, Chen, Ruihuan
• Primary Examiner(s): Wilson, James O.
• Assistant Examiner(s): Krishnan, Ganapathy
• Application Number:
  US10/021,589
• Time in Patent Office: 523 Days
• Field of Search: 564/372, 536/28.1, 536/4.1, 514/25
• US Class Current: 514/25
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07H 19/04 Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Abstract

A compound called NATURA, which is a derivative of Isoindigo is useful in aiding the general health of a patient and specifically is beneficial in preventing or treating cancer. This compound and other related Isoindigo, Indigo and Indirubin derivatives are designed such that the bioactivity or bioavailability of the compound is increased. Also, pharmaceutical compositions that include a therapeutically effective amount of at least one of these derivatives and a pharmaceutically acceptable carrier. A method for the use of these pharmaceutical compositions and compounds is taught, wherein a therapeutically effective amount is administered to an animal. The pharmaceutical composition or compound can be re-administered to the animal until a desired treatment or result is accomplished.

Claims

1. A compound having the following chemical structure:

2. A method for treatment of cancer, comprising administering a therapeutically effective amount of a compound having the following chemical structure:

to an animal.

3. The method of claim 2, wherein said animal is a human.

4. The method of claim 2, wherein the compound is administered in combination with an additional agent selected from the group consisting of radiotherapeutic agents, hormonal therapy agents, immunotherapeutic agents, chemotherapeutic agents, cryotherapeutic agents and gene therapy agents.

5. The method of claim 2, wherein the compound is administered orally.

6. The method of claim 2, wherein the cancer is selected from colon cancer and hormone dependent and independent prostate cancer and breast cancer and lung cancer.

7. A pharmaceutical composition for treatment of cancer in an animal, comprising a therapeutically effective amount of the compound of a compound having the following chemical structure:

and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7, comprising an additional agent selected from the group consisting of radiotherapeutic agents, hormonal therapy agents, immunotherapeutic agents, chemotherapeutic agents, cryotherapeutic agents and gene therapy agents.

9. The pharmaceutical composition of claim 7, wherein the compound is formulated for oral administration.